Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma
about
Advanced MR Imaging in Neuro-oncology.Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyPredictive imaging marker of bevacizumab efficacy: perfusion MRI.Evidence for rCBV as an early response marker following bevacizumab treatment.Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.Pseudoprogression after glioma therapy: an update.Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.Clinical Validation of Automatable Gaussian Normalized CBV in Brain Tumor Analysis: Superior Reproducibility and Slightly Better Association with Survival than Current Standard Manual Normal Appearing White Matter NormalizationImaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q30983681-7F2CC61F-02C0-4C9F-8CF0-5281CB757BC5Q33624367-487A2F73-29E3-4DDD-9089-A68F8E3E2CC5Q36249897-78772CB6-033C-4597-BDCD-0D8F9D5F395BQ36275542-9A79BBB0-1BEF-42B7-9CC7-5200783B8575Q36785131-D82CEFC3-CB9C-4969-928E-B3447EF4CBF7Q38815926-0BEDB943-BDF8-46A8-BD03-6C25BA280B33Q39685607-DBAE0F63-0C06-46D5-A2E1-2CAB762F874CQ40497804-A3BB72FC-EFC9-4003-94F0-9569498809ACQ40721144-1920A98E-D4AD-4FA2-B381-C1F8DA6B145CQ41547838-EAD55DBE-074A-406A-92CD-162C86820811Q42364159-B2283FE9-A8C8-4A5E-9488-CC8479B3A359Q43170408-32895412-BD87-4C78-A673-36E26DCEF943Q43170414-2734BED2-A695-4AB8-A473-B94063117387Q43376098-AA19F648-226D-42C3-BD2F-076A3A5AC4C4Q47167281-705405B9-9473-4D27-A40E-CBEEFBA6D26DQ48130815-0694D975-1672-49EC-81EE-36512F6F254AQ48220641-BE3822FA-5109-486D-9748-BF33ADFCE632Q48918188-5CB227E8-5A14-4CCE-9D0E-86D1F64F9B52Q49499240-908E15A1-53D0-4381-BA05-751BDBA3DFE2Q52365121-FD26A8AA-947B-42A7-8C0D-5431FC8A897EQ52950126-A55C4ABC-39C3-4CBD-895B-29E8BFB897A9Q55456990-E21D2BD0-3635-4B73-96F0-A47118BF493EQ55458839-9A3B9AE8-E93E-4B6F-A318-EFDB68267EAEQ56761469-02CAD4C3-003F-4B46-BD1E-90EE544C906EQ57177114-6A02E0FF-495D-4E13-9E84-31B075907196
P2860
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@ast
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@en
type
label
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@ast
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@en
prefLabel
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@ast
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@en
P2093
P2860
P50
P356
P1433
P1476
Relative cerebral blood volume ...... cacy in recurrent glioblastoma
@en
P2093
Antje Wick
Heinz-Peter Schlemmer
Sabine Heiland
P2860
P304
P356
10.1093/NEUONC/NOV028
P50
P577
2015-03-09T00:00:00Z